An 80-year-old male patient taking trazodone 50 mg and melatonin 12 mg nightly continues to report inability to sleep; what medication should be prescribed?

Discontinue Trazodone and Consider Low-Dose Doxepin or a Non-Benzodiazepine BZRA

The current regimen is ineffective and should be changed—trazodone has poor evidence for insomnia efficacy in older adults, and the melatonin dose is excessive without proven benefit. Based on the 2019 VA/DoD guidelines, you should discontinue trazodone and consider either low-dose doxepin (3-6 mg) or a non-benzodiazepine BZRA (zolpidem, eszopiclone, or zaleplon) at the lowest effective dose 1.

Why Trazodone Is Failing This Patient

The VA/DoD guidelines explicitly advise against trazodone for chronic insomnia based on systematic reviews showing no differences in sleep efficiency or discontinuation rates compared to placebo 1. While trazodone improved subjective sleep quality in some studies, it showed no benefit for sleep onset latency, total sleep time, or wake after sleep onset 1. The evidence supporting trazodone was deemed low-quality with very short study durations (mean 1.7 weeks), and its adverse effect profile outweighed any modest benefits 1.

Recent meta-analyses confirm this: trazodone extends objective total sleep time by only 28 minutes but does not affect perceived sleep duration 2. At 50 mg, it may provide minimal benefit (42 minutes increased sleep time in one small study), but this is insufficient for many patients 3.

Recommended Next Steps

First-Line Pharmacologic Options (After Trazodone Discontinuation):

Option 1: Low-Dose Doxepin (3-6 mg nightly)

• Best for: Sleep maintenance problems (frequent awakenings, early morning awakening)
• Improved insomnia severity scores at 4 weeks in older adults with the 3-6 mg doses 1
• Enhanced subjective sleep latency, total sleep time, and sleep quality 1
• Key advantage: No statistically significant difference in adverse events compared to placebo in RCTs, though adverse events increased with longer treatment 1
• Critical caveat: Suicide risk with low-dose doxepin as a hypnotic is unknown and cannot be excluded 1

Option 2: Non-Benzodiazepine BZRAs (lowest effective dose)

• Zolpidem (5 mg in elderly males), eszopiclone (1-2 mg), or zaleplon (5 mg)
• Improved sleep efficiency, sleep onset latency, sleep quality, total sleep time, and wake after sleep onset compared to placebo 1
• Must counsel patient on: FDA safety warning regarding serious injuries from complex sleep behaviors (sleepwalking, sleep driving) 1
• Use for shortest possible duration at lowest effective dose 1
• Advantage over doxepin: More robust evidence base with 17 RCTs 1

What NOT to Prescribe:

• Benzodiazepines: Strongly contraindicated in this 80-year-old due to falls risk, cognitive impairment, dependency potential, and respiratory depression risk 1
• Antihistamines (diphenhydramine, doxylamine): 2019 Beers Criteria carry strong recommendation to avoid in older adults due to antimuscarinic effects; tolerance develops after 3-4 days 1
• Antipsychotics (quetiapine): Sparse evidence, increased mortality risk in elderly with dementia, not appropriate for primary insomnia 1
• Additional melatonin: Current 12 mg dose already exceeds studied doses (up to 10 mg showed no benefit in AD patients with sleep disturbance) 3. Evidence shows melatonin does not improve total nocturnal sleep time or sleep efficiency in older adults with dementia 3

Practical Implementation Algorithm

1. Discontinue trazodone (taper if used >2 weeks to avoid withdrawal symptoms—anxiety, agitation, sleep problems) 4

2. Reduce melatonin to 3-5 mg or discontinue entirely (current 12 mg dose lacks evidence for additional benefit)

3. Choose based on sleep pattern:

   • Sleep onset insomnia (trouble falling asleep): Zaleplon 5 mg or zolpidem 5 mg
   • Sleep maintenance insomnia (frequent awakenings, early morning awakening): Low-dose doxepin 3-6 mg or eszopiclone 1-2 mg
   • Both onset and maintenance: Eszopiclone 1-2 mg or zolpidem extended-release 6.25 mg

4. Mandatory safety counseling for BZRAs:

   • Risk of complex sleep behaviors (sleepwalking, sleep driving)
   • Take immediately before bed with 7-8 hours available for sleep
   • Avoid alcohol
   • Report any unusual nighttime behaviors immediately

5. For doxepin, screen for:

   • Personal/family history of bipolar disorder (risk of mania activation) 4
   • Cardiac conditions including QT prolongation 4
   • Anatomically narrow angles (risk of angle-closure glaucoma) 4
   • Current use of anticoagulants (increased bleeding risk) 4

Critical Safety Considerations in This 80-Year-Old

• Orthostatic hypotension risk: Both trazodone (current medication) and doxepin can cause this; monitor blood pressure supine and standing 4
• Falls risk: All sedative-hypnotics increase fall risk in elderly; ensure home safety assessment
• Cognitive impairment: BZRAs can impair next-day cognition; start lowest dose and assess morning function
• Polypharmacy interactions: Review all medications for drug-drug interactions, particularly with CYP3A4 inhibitors that could increase BZRA levels

Duration of Treatment

• BZRAs: Use for shortest possible duration (ideally <4 weeks), reassess regularly 1
• Low-dose doxepin: Can be used longer-term but monitor for adverse effects that increase with duration 1
• Strongly recommend concurrent cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with medication as adjunct 1

The evidence clearly shows trazodone 50 mg is inadequate for this patient's insomnia 1, 2. Switching to evidence-based alternatives with proper safety monitoring offers the best chance for symptom improvement while minimizing harm in this elderly patient.